149394-66-1

149394-66-1 structure

Name: Cidofovir Dihydrate
Chemical Name: cidofovir dihydrate
CAS Number: 149394-66-1
Molecular Formula: C₈H₁₈N₃O₈P
Molecular Weight: 315.22
Catalog: API Synthetic anti-infective drugs Antiviral drugs
Create Date: 2018-04-24 08:00:00
Modify Date: 2024-01-04 16:01:15
Cidofovir dehydrate is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis, which suppresses virus replication by selective inhibition of viral DNA synthesis.Target: CMV DNA polymeraseCidofovir is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA polymerase and therefore prevention of viral replication and transcription. It is an acyclic nucleoside phosphonate, and is therefore independent of phosphorylation by viral enzymes, unlike acyclovir.Cidofovir was discovered at the Institute of Organic Chemistry and Biochemistry, Prague, by Antonín Hol?, and developed by Gilead Sciences and is marketed with the brand name Vistide by Gilead in the USA, and by Pfizer elsewhere. Maintenance therapy with cidofovir involves an infusion only once every two weeks, making it a convenient treatment option. Because dosing is relatively infrequent, a permanent catheter is not necessary for infusions.

Name	cidofovir dihydrate
Synonyms	Cidofovir hydrate (1:2) Gs-0504 Phosphonic acid, [[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]- Cidofovir dihydrate ({[(2S)-1-(4-Amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid Cidofovir (S)-[[2-(4-Amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic Acid Unii-jil713Q00n (S)-HPMPC Hydrate Cidovir Hydrate Vistide Hydrate (S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl-1-(hydroxymethyl)ethoxy)methyl phosphonic acid ({[(2S)-1-(4-Amino-2-oxo-1(2H)-pyrimidinyl)-3-hydroxy-2-propanyl]oxy}methyl)phosphonic acid Vistide Drg-0145 Cidofovir hydrate GS 0504 Hydrate Cidofovir (dihydrate)

Description	Cidofovir dehydrate is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis, which suppresses virus replication by selective inhibition of viral DNA synthesis.Target: CMV DNA polymeraseCidofovir is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA polymerase and therefore prevention of viral replication and transcription. It is an acyclic nucleoside phosphonate, and is therefore independent of phosphorylation by viral enzymes, unlike acyclovir.Cidofovir was discovered at the Institute of Organic Chemistry and Biochemistry, Prague, by Antonín Hol?, and developed by Gilead Sciences and is marketed with the brand name Vistide by Gilead in the USA, and by Pfizer elsewhere. Maintenance therapy with cidofovir involves an infusion only once every two weeks, making it a convenient treatment option. Because dosing is relatively infrequent, a permanent catheter is not necessary for infusions.
Related Catalog	Signaling Pathways >> Anti-infection >> CMV Research Areas >> Infection
References	[1]. Becker MN, et al. Isolation and characterization of cidofovir resistant vaccinia viruses. Virol J. 2008 May 14;5:58. [2]. Kazory A, et al. Simultaneous development of Fanconi syndrome and acute renal failure associated with cidofovir. J Antimicrob Chemother. 2007 Jul;60(1):193-4. Epub 2007 May 11. [3]. Segarra-Newnham M, et al. Use of cidofovir in progressive multifocal leukoencephalopathy. Ann Pharmacother. 2001 Jun;35(6):741-4.

Density	1.8±0.1 g/cm3
Boiling Point	609.5±65.0 °C at 760 mmHg
Melting Point	260ºC (dec)
Molecular Formula	C₈H₁₈N₃O₈P
Molecular Weight	315.22
Flash Point	322.4±34.3 °C
PSA	157.71000
LogP	-3.37
Vapour Pressure	0.0±4.0 mmHg at 25°C
Index of Refraction	1.656

149394-66-1	142276-31-1
113852-37-2	3687-64-7
40935-29-3	140480-49-5
688358-20-5	16393-28-5
21439-54-3	919080-10-7